The Ph.D. Program in Translational and Molecular Medicine (Dimet) is an inter-departmental project organized by the Doctorate School of Milano-Bicocca University. Dimet represents a comprehensive answer to a cultural challenge focused on the recent advances and success of the bio-medical research area and on the resulting modern technological applications. The post-genomic era is leading to a revolution in the understanding of human diseases and their treatments. However, the possibility of elucidating cellular and molecular mechanisms that regulate complex systems needs a deeply interaction between basic and applied research. This requires the formation of “translational” professional profiles with a robust background in basic research, but also equipped to bridge the gap between bench and clinical investigation.

Project description: Prof. Carlo Gambacorti-Passerini is a leading physician/scientist in the field of oncogenic fusion proteins and tyrosine kinase inhibitors. GCP has contributed significantly to the development of imatinib for the treatment of CML and he was the first researcher who successfully treated an ALK+ lymphoma patient with an ALK inhibitor. He supervised several MSc/PhD students and post-docs (>35) during the past 15 years. He co-authored >180 peer-reviewed papers. The laboratory led by Prof. Carlo Gambacorti-Passerini at Unimib is equipped with all necessary instruments for the proposed research, including an Illumina platform for NGS, Exome sequencing and tools for bioinformatics analysis of the data. Some bioinformatics software was originally developed inside his group. A mouse facility is available at Unimib and routinely used by Prof. Gambacorti-Passerini’s staff. Prof. Gambacorti-Passerini is the Director of the Clinical Research Unit at San Gerardo Hospital in Monza, next to the University. He has free access to biological samples from Crizotinib-treated patients, obtained after informed consent and clearance from the local Ethical Committee.

Requirements:

• All researchers recruited in an ITN (Marie Skłodowska-Curie Actions) must be Early-Stage Researchers (ESRs) and undertake transnational mobility. For all recruitments, the eligibility of the researcher will be determined at the time of their first recruitment in the project. The status of the researcher will not evolve over the life-time of the project, even if they are re-recruited at another beneficiary. Mobility of Researchers: researchers can be of any nationality. They are required to undertake transnational mobility (i.e. move from one country to another) when taking up their appointment.

• master degree in molecular biology, genetics, biochemistry or similar field

• good knowledge of English

• systematic, responsible and positive attitude

• good communication, flexibility and interpersonal skills

Offer:

We offer a contract for 3 years, competitive salary and challenging work in friendly environment and dynamic team. Start of the work is expected between January and February 2016.

Please send a structured CV (including references) and a short motivation letter, both in English, to E-mail address: carlo.gambacorti@unimib.it, by 30th September, 2015.

Type of employment: Full Time